New adjuvants in evolving vaccine strategies.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 21609186)

Published in Expert Opin Biol Ther on May 24, 2011

Authors

Franco M Buonaguro1, Maria Lina Tornesello, Luigi Buonaguro

Author Affiliations

1: Molecular Biology and Viral Oncology, Dpt of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Napoli, Italy. fm.buonaguro@istitutotumori.na.it

Articles by these authors

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24

Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17

Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13

Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09

Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06

Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology (2015) 1.03

Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol (2006) 1.02

Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med (2012) 0.99

Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer (2008) 0.99

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98

Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol (2012) 0.97

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96

Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol (2008) 0.96

Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol (2013) 0.95

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95

Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92

Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines (2011) 0.91

Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines (2009) 0.91

Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89

Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J Acquir Immune Defic Syndr (2004) 0.89

Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology (2010) 0.89

Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. J Clin Virol (2009) 0.88

Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol (2013) 0.87

Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? Immunotherapy (2011) 0.87

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer (2011) 0.87

Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol (2011) 0.85

High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta (2009) 0.84

VLPs and particle strategies for cancer vaccines. Expert Rev Vaccines (2013) 0.83

Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83

Human papillomavirus infection in urine samples from male renal transplant patients. J Med Virol (2010) 0.83

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers (2010) 0.82

Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology (2007) 0.82

Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells. PLoS One (2012) 0.82

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med (2014) 0.82

TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology (2009) 0.82

Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. Infect Agent Cancer (2013) 0.82

A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women. J Med Virol (2008) 0.82

The application of virus-like particles to human diseases. Expert Rev Vaccines (2013) 0.81

Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathol Oncol Res (2012) 0.81

TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev (2005) 0.81

Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res (2011) 0.81

Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infect Agent Cancer (2008) 0.81

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration. Clin Vaccine Immunol (2012) 0.81

Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. J Virol Methods (2005) 0.80

Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol Immunother (2015) 0.80

High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy. APMIS (2011) 0.80

An overview of new biomolecular pathways in pathogen-related cancers. Future Oncol (2015) 0.79

HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer (2012) 0.79

Developments in virus-like particle-based vaccines for HIV. Expert Rev Vaccines (2013) 0.78

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model. PLoS One (2013) 0.78

Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol (2014) 0.78

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. J Transl Med (2013) 0.78

Cellular prognostic markers in hepatocellular carcinoma. Future Oncol (2015) 0.78

Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. New Microbiol (2012) 0.77

Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. Cancer Lett (2008) 0.77

Report on the AIDS Vaccine 2008 Conference. Hum Vaccin (2009) 0.77

HIV p24 as scaffold for presenting conformational HIV Env antigens. PLoS One (2012) 0.77

Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. Expert Rev Vaccines (2010) 0.77

Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. J Transl Med (2014) 0.77

Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One (2012) 0.77

Can HIV p24 be a suitable scaffold for presenting Env antigens? Clin Vaccine Immunol (2011) 0.76

Immunogenomics approaches for vaccine evaluation. J Immunotoxicol (2012) 0.76

Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76

Assessment of Chlamydia trachomatis infection among Eastern European and West African women immigrants in South Italy. Sex Transm Infect (2011) 0.76

Quantitative HIV-1 proviral DNA detection: a multicentre analysis. New Microbiol (2010) 0.75

Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. PLoS One (2015) 0.75

Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. J Transl Med (2013) 0.75

Oncolytic virus therapies. Pharm Pat Anal (2012) 0.75

An overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases. Mini Rev Med Chem (2017) 0.75

Unsung hero Robert C. Gallo. Science (2009) 0.75

Advances in viral oncology research: summary of the 3rd International Meeting. Expert Rev Vaccines (2012) 0.75

Systems vaccinology for cancer vaccine development. Expert Rev Vaccines (2014) 0.75